CureVac，MD Anderson合作研制癌症疫苗

2024-04-16 19:59

CureVac (NASDAQ:CVAC) and the University of Texas MD Anderson Cancer Center announced a co-development and licensing pact to develop novel, off-the-shelf, mRNA-based cancer vaccines for selected hematological and solid cancers with high unmet medical needs.
The alliance creates strong synergies between CureVac's unique end-to-end mRNA capabilities and MD Anderson's translational and clinical research expertise.
Both parties will work on identifying differentiated cancer antigens using whole genome sequencing, RNA sequencing, and bioinformatics.
The joint preclinical validation will be conducted, supported by Sachet Shukla and MD Anderson's ECLIPSE platform.
Under the partnership, MD Anderson will be responsible for leading initial Phase 1/2 studies after the completion of investigational new drug approvals, and CureVac will retain worldwide exclusive rights to late-stage development, commercialization, or partnering of cancer vaccine candidates.
Additionally, as per the partnership terms, MD Anderson is eligible for certain downstream payments based on potential future commercialization.

More on CureVac BV